<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/F8302422-55CA-4DFF-817B-9EBECA831882"><gtr:id>F8302422-55CA-4DFF-817B-9EBECA831882</gtr:id><gtr:name>The Global Alliance for TB Drug Development</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FFDE1B31-6FE1-4451-8471-23644FFEB793"><gtr:id>FFDE1B31-6FE1-4451-8471-23644FFEB793</gtr:id><gtr:name>Vietnam National Lung Hospital</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/CCCAF38E-905A-4201-A354-906F1BC43502"><gtr:id>CCCAF38E-905A-4201-A354-906F1BC43502</gtr:id><gtr:name>Shanghai Institute of Organic Chemistry (SIOC)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FC48271D-57EB-4AB8-ACF9-B104EB984FA6"><gtr:id>FC48271D-57EB-4AB8-ACF9-B104EB984FA6</gtr:id><gtr:name>Vietnam Academy of Science and Technology</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/39C42C5C-3927-494A-A68A-208FEC89F7F9"><gtr:id>39C42C5C-3927-494A-A68A-208FEC89F7F9</gtr:id><gtr:name>Grifols</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11"><gtr:id>8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11</gtr:id><gtr:name>Vietnam National University (VNU)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/035E7435-BA5D-4775-9837-6EC2C8323A30"><gtr:id>035E7435-BA5D-4775-9837-6EC2C8323A30</gtr:id><gtr:name>Guangdong University of Technology</gtr:name><gtr:address><gtr:line1>729 East Dongfeng Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B711AB39-A8D5-4894-A0A7-23C4BC8AF157"><gtr:id>B711AB39-A8D5-4894-A0A7-23C4BC8AF157</gtr:id><gtr:name>Shanghai Jiao Tong University</gtr:name><gtr:address><gtr:line1>1954 Huashan Road</gtr:line1><gtr:line4>Shanghai</gtr:line4><gtr:line5>200030</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FAB4882A-ED6B-40DF-A638-DA756984D090"><gtr:id>FAB4882A-ED6B-40DF-A638-DA756984D090</gtr:id><gtr:name>Absolute Antibody Ltd.</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3ED60B49-9C2B-4D71-B644-96CCC7F10194"><gtr:id>3ED60B49-9C2B-4D71-B644-96CCC7F10194</gtr:id><gtr:name>Liverpool School of Tropical Medicine</gtr:name><gtr:address><gtr:line1>School Of Tropical Medicine</gtr:line1><gtr:line2>Pembroke Place</gtr:line2><gtr:postCode>L3 5QA</gtr:postCode><gtr:region>North West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B6FB652A-60C3-48DD-9A33-075D1F759B48"><gtr:id>B6FB652A-60C3-48DD-9A33-075D1F759B48</gtr:id><gtr:name>University of Warwick</gtr:name><gtr:address><gtr:line1>Warwickshire</gtr:line1><gtr:line4>Coventry</gtr:line4><gtr:line5>West Midlands</gtr:line5><gtr:postCode>CV4 7AL</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/F8302422-55CA-4DFF-817B-9EBECA831882"><gtr:id>F8302422-55CA-4DFF-817B-9EBECA831882</gtr:id><gtr:name>The Global Alliance for TB Drug Development</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF"><gtr:id>C4ED5B1E-E265-4B92-8BF2-EBDB7897E0CF</gtr:id><gtr:name>Centers for Disease Control and Prevention (CDC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FFDE1B31-6FE1-4451-8471-23644FFEB793"><gtr:id>FFDE1B31-6FE1-4451-8471-23644FFEB793</gtr:id><gtr:name>Vietnam National Lung Hospital</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1367D45-734D-4891-9671-3C7C7C31D0A0"><gtr:id>D1367D45-734D-4891-9671-3C7C7C31D0A0</gtr:id><gtr:name>UCB Pharma</gtr:name><gtr:address><gtr:line1>Researchdreef 60</gtr:line1><gtr:line2>Allee de la Recherche 60</gtr:line2><gtr:postCode>B-1070</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Belgium</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/CCCAF38E-905A-4201-A354-906F1BC43502"><gtr:id>CCCAF38E-905A-4201-A354-906F1BC43502</gtr:id><gtr:name>Shanghai Institute of Organic Chemistry (SIOC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FC48271D-57EB-4AB8-ACF9-B104EB984FA6"><gtr:id>FC48271D-57EB-4AB8-ACF9-B104EB984FA6</gtr:id><gtr:name>Vietnam Academy of Science and Technology</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/39C42C5C-3927-494A-A68A-208FEC89F7F9"><gtr:id>39C42C5C-3927-494A-A68A-208FEC89F7F9</gtr:id><gtr:name>Grifols</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11"><gtr:id>8DB38BE9-A921-41DE-B6EC-A43C3BB0EA11</gtr:id><gtr:name>Vietnam National University (VNU)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A0A585E0-6B0D-4643-A3A6-47943B4CBFEF"><gtr:id>A0A585E0-6B0D-4643-A3A6-47943B4CBFEF</gtr:id><gtr:name>University of Liverpool</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line2>Abercromby Square</gtr:line2><gtr:line4>Liverpool</gtr:line4><gtr:postCode>L69 3BX</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>London</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/035E7435-BA5D-4775-9837-6EC2C8323A30"><gtr:id>035E7435-BA5D-4775-9837-6EC2C8323A30</gtr:id><gtr:name>Guangdong University of Technology</gtr:name><gtr:address><gtr:line1>729 East Dongfeng Road</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B711AB39-A8D5-4894-A0A7-23C4BC8AF157"><gtr:id>B711AB39-A8D5-4894-A0A7-23C4BC8AF157</gtr:id><gtr:name>Shanghai Jiao Tong University</gtr:name><gtr:address><gtr:line1>1954 Huashan Road</gtr:line1><gtr:line4>Shanghai</gtr:line4><gtr:line5>200030</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>China</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9D53091E-603E-4B64-B5EC-6430D28827FD"><gtr:id>9D53091E-603E-4B64-B5EC-6430D28827FD</gtr:id><gtr:name>Syngenta</gtr:name><gtr:address><gtr:line1>WRO-1004.1.51</gtr:line1><gtr:line2>Schwarzwaldallee 215</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E20F47CA-8AB4-4F4D-A90D-A290834C65FF"><gtr:id>E20F47CA-8AB4-4F4D-A90D-A290834C65FF</gtr:id><gtr:name>University Hospital Coventry NHS Trust</gtr:name><gtr:address><gtr:line1>Clifford Bridge Road</gtr:line1><gtr:line2>Walsgrave</gtr:line2><gtr:postCode>CV2 2DX</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FAB4882A-ED6B-40DF-A638-DA756984D090"><gtr:id>FAB4882A-ED6B-40DF-A638-DA756984D090</gtr:id><gtr:name>Absolute Antibody Ltd.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/35C0CE50-61C8-4951-A6BD-C121ABC82F8E"><gtr:id>35C0CE50-61C8-4951-A6BD-C121ABC82F8E</gtr:id><gtr:firstName>Stephen</gtr:firstName><gtr:surname>Ward</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_12017"><gtr:id>2345C1CD-65B3-457F-8A8E-64D29583FB6A</gtr:id><gtr:title>Confidence in Concept 2012 - Liverpool school of Tropical Medicine</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_12017</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>The Confidence in Concept scheme is a key part of MRC?s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach ?? before seeking more substantive funding.&amp;nbsp; It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-05</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-11-05</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>250000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University of Warwick</gtr:description><gtr:id>4BEC9A06-6083-4545-B9F0-2B1E330B3957</gtr:id><gtr:impact>Papers</gtr:impact><gtr:outcomeId>545b53bddbe0d5.12278133-1</gtr:outcomeId><gtr:partnerContribution>Our collaborator at Warwick investigated interactions with DC-SIGN</gtr:partnerContribution><gtr:piContribution>We developed mutated Fc-proteins</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Jenner Institute</gtr:department><gtr:description>Jenner Institute</gtr:description><gtr:id>4869086F-6697-440D-95CD-DCC1CD1D7368</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:outcomeId>581c674d3450c8.40498558-1</gtr:outcomeId><gtr:partnerContribution>The Jenner will test the immunogenicity of these constructs in animal models of malaria</gtr:partnerContribution><gtr:piContribution>We have designed new constructs for delivering antigens in malaria vaccines.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Guangdong University of Technology</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Guangdong University of Technology, China (GDUT)</gtr:description><gtr:id>077CDE0A-590B-48AB-8085-A15D4D55079C</gtr:id><gtr:impact>Compounds have been synthesised and teaching programs are being developed by the consortium</gtr:impact><gtr:outcomeId>545ced103a3f92.62616490-1</gtr:outcomeId><gtr:partnerContribution>We have set up a Liverpool-Guangdong Drug Discovery Consortium. The consortium, made up of LSTM, University of Liverpool (UoL), Department of Chemistry and the Department of Pharmacy Engineering, Guangdong University of Technology, China (GDUT), is focussed on the development of new drug therapies for the treatment of TB, Malaria and other infectious diseases. A new laboratory has been opened known as the &amp;quot; Liverpool-Guangzhou drug discovery joint laboratory&amp;quot;, located at GDUT. The laboratory will accommodate a drug discovery team made up of staff and students from GDUT and other parts of China. Pre-clinical projects targeting TB as well as malaria and NTD infections will be co-developed by the consortium.</gtr:partnerContribution><gtr:piContribution>We have set up a Liverpool-Guangdong Drug Discovery Consortium. The consortium, made up of LSTM, University of Liverpool (UoL), Department of Chemistry and the Department of Pharmacy Engineering, Guangdong University of Technology, China (GDUT), is focussed on the development of new drug therapies for the treatment of TB, Malaria and other infectious diseases. A new laboratory has been opened known as the &amp;quot; Liverpool-Guangzhou drug discovery joint laboratory&amp;quot;, located at GDUT. The laboratory will accommodate a drug discovery team made up of staff and students from GDUT and other parts of China. Pre-clinical projects targeting TB as well as malaria and NTD infections will be co-developed by the consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospitals Coventry and Warwickshire NHS Trust</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>University Hospital Coventry and Warwickshire</gtr:description><gtr:id>56A58845-3F4A-474E-9BB7-5997B034C4BB</gtr:id><gtr:impact>PMID: 24018955 
PMID: 23201982 
PMID: 23478806 
PMID: 22764881</gtr:impact><gtr:outcomeId>SbgwXisbj8v-1</gtr:outcomeId><gtr:partnerContribution>UHCW will recruit TB patients and controls from the hospital for the enose study. The e-nose technology will be set up in their Cat III area, and samples will be run on site</gtr:partnerContribution><gtr:piContribution>The research team work effectively with UHCW providing technology and tools for novel diagnosis of patients. Research protocols and ethical approvals are completed in collaboration, and supervision is provided.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shanghai Institute of Organic Chemistry (SIOC)</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Shanghai Institute of Organic Chemistry (SIOC.)</gtr:description><gtr:id>3ED3BC0D-47EA-4B73-881B-04F41AADE4CE</gtr:id><gtr:impact>Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical.</gtr:impact><gtr:outcomeId>545cee56bbd5b5.30539922-1</gtr:outcomeId><gtr:partnerContribution>Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical.</gtr:partnerContribution><gtr:piContribution>Shanghai Institute of Organic Chemistry (SIOC.) and the Liverpool groups have begun a collaboration in drug discovery programs. SIOC is providing chemical compounds for screening and helping with complex synthetic routes whilst the Liverpool team is providing testing against TB, malaria and NTDs as well as full pre-clinical support (e.g. pharmacology, biology, med chem), to and clinical.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Centers for Disease Control and Prevention (CDC)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Bacterial Pathogenesis</gtr:department><gtr:description>P4 collaboration group for DPFS bid</gtr:description><gtr:id>A0CE8A0E-1866-4219-AF84-A0A0C34581BA</gtr:id><gtr:impact>We have been shortlisted for a DPFS award</gtr:impact><gtr:outcomeId>qncdtHHHCYc-1</gtr:outcomeId><gtr:partnerContribution>CDC Atlanta provide P4 and intellectual input
ITU teams recruit patients
We collect samples
Our lab and Kadioglu lab run assays ex vivo.</gtr:partnerContribution><gtr:piContribution>We lead a group consisting of 2 hospital ITU teams, 3 laboratories and research teams focusing on developing the clinical use of the P4 peptide.</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>AstraZeneca</gtr:description><gtr:id>D2E17BF8-8384-4A81-95C8-D1DD13BD36E8</gtr:id><gtr:impact>multidisciplinary collaboration. The project is still on going and only hit molecules identified thus far. Lead series will be identified in the next 12 months.</gtr:impact><gtr:outcomeId>V7ZVJV3TvEb-1</gtr:outcomeId><gtr:partnerContribution>AstraZeneca are providing starting points (hits) for testing against TB and malaria and they are also providing HTS expertise, chemoinformatics and ADMET screening. AZ collaborating partners are based both in the UK and India. Aspects of this collaboration are also within the WIPO (World intellectual Property Organisation) umbrella.</gtr:partnerContribution><gtr:piContribution>A collaboration is underway for both malaria and TB drug discovery. LSTM research team are providing in vitro and in vivo PD and PK models and expertise in drug discovery for these specific diseases. Aspects of this collaboration are also within the WIPO (World intellectual Property Organisation) umbrella.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Astra Zeneca repurposing drugs</gtr:description><gtr:id>FEE90C5B-D5DD-463C-AE90-FF7F26A95736</gtr:id><gtr:impact>Still in progress</gtr:impact><gtr:outcomeId>5460d5f437d450.73682787-1</gtr:outcomeId><gtr:partnerContribution>Provision of compounds for testing</gtr:partnerContribution><gtr:piContribution>Assessing anti infective potential of AZ repurposing molecules.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Grifols</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Research and Development</gtr:department><gtr:description>P4 collaboration group for DPFS bid</gtr:description><gtr:id>E663AE30-7185-48B6-8E22-4AFE028B6E2D</gtr:id><gtr:impact>We have been shortlisted for a DPFS award</gtr:impact><gtr:outcomeId>qncdtHHHCYc-3</gtr:outcomeId><gtr:partnerContribution>CDC Atlanta provide P4 and intellectual input
ITU teams recruit patients
We collect samples
Our lab and Kadioglu lab run assays ex vivo.</gtr:partnerContribution><gtr:piContribution>We lead a group consisting of 2 hospital ITU teams, 3 laboratories and research teams focusing on developing the clinical use of the P4 peptide.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vietnam National University (VNU)</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam</gtr:description><gtr:id>0A539AD5-CEFE-40B9-B2FE-0549CB7E18DC</gtr:id><gtr:impact>Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017.</gtr:impact><gtr:outcomeId>58c6903d060f08.78643982-2</gtr:outcomeId><gtr:partnerContribution>The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme.</gtr:partnerContribution><gtr:piContribution>This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>The Global Alliance for TB Drug Development</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>TB Alliance</gtr:description><gtr:id>D2D63556-1B83-4769-BBDA-09D0E26F055A</gtr:id><gtr:impact>TBAlliance are providing support in the way of in vivo PK and TB in vivo drug efficacy models (rodent acute model)

If successful this will form the basis of a more extensive drug development programme</gtr:impact><gtr:outcomeId>545ce90db19483.85570640-1</gtr:outcomeId><gtr:partnerContribution>TBAlliance have conducted in vivo PK studies on our lead compounds and we will shortly be conducting in vivo drug efficacy experiments using their TB drug development network

If successful this will form the basis of a more extensive drug development programme</gtr:partnerContribution><gtr:piContribution>We have developed inhibitors via the MRC funded project that are at lead stage - these are being tested presently. We are also in discussions with TBA regarding our high content imaging platform, the development of which is supported via a MRC CiC award</gtr:piContribution><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Shanghai Jiao Tong University</gtr:collaboratingOrganisation><gtr:country>China, People's Republic of</gtr:country><gtr:description>Shanghai Jiao Tong University</gtr:description><gtr:id>007F725A-3DC2-4ABD-BBC2-59958A4D9DA8</gtr:id><gtr:impact>Papers, more research</gtr:impact><gtr:outcomeId>545b56124d14a0.83714244-1</gtr:outcomeId><gtr:partnerContribution>Our partners use state of the art cryo Atomic Force Microscopy to image the molecules we make</gtr:partnerContribution><gtr:piContribution>We make mutant Fcs and oligomeric Fc</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vietnam National Lung Hospital</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam</gtr:description><gtr:id>B0F251B8-CDC6-49ED-BF37-11656AB84FE2</gtr:id><gtr:impact>Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017.</gtr:impact><gtr:outcomeId>58c6903d060f08.78643982-1</gtr:outcomeId><gtr:partnerContribution>The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme.</gtr:partnerContribution><gtr:piContribution>This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Imperial College</gtr:description><gtr:id>818E1339-3ABD-4BEC-B0E3-FAD366987D41</gtr:id><gtr:impact>papers</gtr:impact><gtr:outcomeId>545b5748997196.33254108-1</gtr:outcomeId><gtr:partnerContribution>Our partners characterised the glycans on these molecules</gtr:partnerContribution><gtr:piContribution>We made Fc-proteins</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Syngenta</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Syngenta Ltd (Bracknell)</gtr:department><gtr:description>Access to Syngenta Compunds</gtr:description><gtr:id>936F0C94-E795-4019-B0E6-97F9CB146778</gtr:id><gtr:impact>Still in progress</gtr:impact><gtr:outcomeId>546099cd04abd5.32238227-1</gtr:outcomeId><gtr:partnerContribution>Syngenta have agreed to provide up to 0.5million compounds for screening as potential antimalarial starting points and they have given us access to the structures to continue and enhance our research in this area.</gtr:partnerContribution><gtr:piContribution>An agreement has been reached with Sygnenta for us to gain access and screen numerous compounds for anti infective activity</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Absolute Antibody Ltd.</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Absolute Antibody</gtr:description><gtr:id>B66C05A8-EBA8-4A52-9FEE-CF0BDB2C3084</gtr:id><gtr:impact>We have made novel constructs based on our MRC CiC award that we have now under MTA provided to Absolute Antibody.
They will now try and functionalism our molecules with an aim to develop new diagnostics.</gtr:impact><gtr:outcomeId>581c6632a1ac52.86544100-1</gtr:outcomeId><gtr:partnerContribution>See above</gtr:partnerContribution><gtr:piContribution>We have made novel constructs based on our MRC CiC award that we have now under MTA provided to Absolute Antibody.
They will now try and functionalism our molecules with an aim to develop new diagnostics.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Warwick</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Engineering</gtr:department><gtr:description>Warwick University</gtr:description><gtr:id>A52BD6DC-B314-4C76-865B-2E54CE2C6497</gtr:id><gtr:impact>PMID: 22764881 PMID: 23478806 PMID: 23201982 PMID: 24018955</gtr:impact><gtr:outcomeId>FmR4XWpcUnQ-1</gtr:outcomeId><gtr:partnerContribution>UOW work on enose and sensor technology. Engineering novel, and appropriate diagnostics for developing world.</gtr:partnerContribution><gtr:piContribution>LSTM provides diagnostic evaluation advice to UOW, collaboration on writing protocols and ethical approval. Guidance for appropriate technology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Liverpool</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Infection and Global Health</gtr:department><gtr:description>P4 collaboration group for DPFS bid</gtr:description><gtr:id>BB4A4A03-C334-4270-9459-20B1C9B004CF</gtr:id><gtr:impact>We have been shortlisted for a DPFS award</gtr:impact><gtr:outcomeId>qncdtHHHCYc-2</gtr:outcomeId><gtr:partnerContribution>CDC Atlanta provide P4 and intellectual input
ITU teams recruit patients
We collect samples
Our lab and Kadioglu lab run assays ex vivo.</gtr:partnerContribution><gtr:piContribution>We lead a group consisting of 2 hospital ITU teams, 3 laboratories and research teams focusing on developing the clinical use of the P4 peptide.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Physics and Astronomy</gtr:department><gtr:description>University of Leeds</gtr:description><gtr:id>ED2FD61A-E133-4B9B-A43E-ED29C7182073</gtr:id><gtr:impact>In process</gtr:impact><gtr:outcomeId>581c7a9d0c4d97.55157455-1</gtr:outcomeId><gtr:partnerContribution>Provided the adhiron sequences</gtr:partnerContribution><gtr:piContribution>We have cloned adhirons from Leeds onto our hexa-Fc platform. And developed novel adhirons specific for pneumolysin with which to treat meningitis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>UCB Pharma</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UCB Pharma</gtr:description><gtr:id>3CB9756E-4A2D-4782-BA51-B18881D8BCCD</gtr:id><gtr:impact>The joint agreement is still under review</gtr:impact><gtr:outcomeId>545b5077d39c55.51433595-1</gtr:outcomeId><gtr:partnerContribution>see above</gtr:partnerContribution><gtr:piContribution>As a consequence of MRC CIC investment we are in the process of licensing two patents and a trademark to UCB Pharma.
Under the joint agreement UCB Pharma are funding an 18 month project to develop the prototype molecule.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:department>Tres Cantos Medicines Development Campus</gtr:department><gtr:description>Collaboration with GSK</gtr:description><gtr:id>BD28753E-3C18-45C4-AB67-9E69295E24F9</gtr:id><gtr:impact>The team has generated early leads targeting a novel biological target in M. tuberculosis</gtr:impact><gtr:outcomeId>PyYcHEhgYmA-1</gtr:outcomeId><gtr:partnerContribution>The GSK team is part of the product development team and specifically carries out in vivo antitubercular testing in their acute and chronic models</gtr:partnerContribution><gtr:piContribution>The Liverpool research team undertakes early phase drug discovery of new anti-tuberculosis compounds which includes HTS screening, predictive in vitro models, medicinal chemistry, in vitro ADMET and in vivo DMPK</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Vietnam Academy of Science and Technology</gtr:collaboratingOrganisation><gtr:country>Vietnam, Socialist Republic of</gtr:country><gtr:description>Using pharmacokinetic - pharmacodynamic analyses to select optimal dosing for non-MDR pulmonary TB treatment failure patients in Vietnam</gtr:description><gtr:id>5F8D10A5-01FA-4CE1-B46B-0DC76706560A</gtr:id><gtr:impact>Uk researchers have been involved in training VN researchers in the UK and Ethics applications have been submitted and approved for the clinical study due to begin in May 2017.</gtr:impact><gtr:outcomeId>58c6903d060f08.78643982-3</gtr:outcomeId><gtr:partnerContribution>The collaboration is between the UK and a number of institutions in VN (listed above). The project is specifically trying to address the underlying reasons for TB treatment failures but in terms of training, UK researchers are providing training in Pharmacology, specifically pharmacokinetics and PK-PD modelling, addressing a specific expertise gap in VN and the National TB Programme.</gtr:partnerContribution><gtr:piContribution>This collaboration has been funded via the MRC-Newton call in collaboration with the MOST ministry of Vietnam</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:description>University of Oslo</gtr:description><gtr:id>56421F31-D466-4987-AA14-11AF81DFDADA</gtr:id><gtr:impact>Papers</gtr:impact><gtr:outcomeId>545b53091f93a5.42761529-1</gtr:outcomeId><gtr:partnerContribution>Our partners investigated the interaction of our mutant proteins to FcRn</gtr:partnerContribution><gtr:piContribution>We made mutant proteins</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Human Challenge Models workshop</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>AA1384FF-6FA0-400D-B664-609377CAAE2F</gtr:id><gtr:impact>Lancet Infectious Diseases report as per papers

MRC Programme grant Expt Human Pneumococcal Carriage funded Nov 2014</gtr:impact><gtr:outcomeId>545cb3820bd355.43905528</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at the 2014 Towards New Therapeutics for Diseases of the Developing World Conference, Spain</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A44F1D19-803D-44EF-8335-752C036A2D0D</gtr:id><gtr:impact>Talk sparked Q&amp;amp;A session and discussion afterwards

n/a</gtr:impact><gtr:outcomeId>5462137b3f6f37.67702283</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>P4 CIC - ICUsteps</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>551CF390-1352-43DA-A107-FBF4F7029E3B</gtr:id><gtr:impact>We have engaged with ICUsteps, a national organisation that supports ex-critical care patients recovering after critical illness. Members of this organisation have advised in preparation of the Sepsis project and also for submission of the fellowship proposal</gtr:impact><gtr:outcomeId>56b089ef4cec36.76898536</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HOWSTUFFWORKS</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>FBC95E14-2A3A-40F8-8C37-833FB2963D56</gtr:id><gtr:impact>Viking Toilet Worm Investigation Finds Genetic Clues to Emphysema's Origins</gtr:impact><gtr:outcomeId>581c6f22d9cdb8.84781945</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://now.howstuffworks.com/2016/02/12/viking-toilet-investigation-emphysema#!</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ITU conference 2013</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9D228E98-B5B9-4086-A544-75896EC89934</gtr:id><gtr:impact>Presented to ITU clinicians and have now engaged 2 ITU teams in P4 research.

ITU groups now welcome phase 2 study.</gtr:impact><gtr:outcomeId>545cb3042f3336.56509799</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Radio interview</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>827245BA-495A-40F7-A05B-06E90F80DCA6</gtr:id><gtr:impact>local and regional radio interviews

public engagement</gtr:impact><gtr:outcomeId>S5QFxSTomqw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>presentation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>DD223559-820A-4DEA-BCB0-EB2A6E87CFB2</gtr:id><gtr:impact>WIDER group on Enose technology

Networking opportunity</gtr:impact><gtr:outcomeId>H3WBXUe6uQC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>IFLS Blog - Viking Worm Infestation May Provide Genetic Link To Modern Lung Disease</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>05775B7F-3E6E-414E-B5F0-96B054347B34</gtr:id><gtr:impact>Viking Worm Infestation May Provide Genetic Link To Modern Lung Disease Blog</gtr:impact><gtr:outcomeId>581c6e2dcaacb8.86342662</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://www.iflscience.com/health-and-medicine/viking-worm-infestation-may-provide-genetic-link-modern-lung-disease/</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Festival - Lancashire</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E299B260-CF19-4DAE-95A6-A8DFF92E250B</gtr:id><gtr:impact>June 2013 the Lancashire Science Festival at UCLAN took part in 'I'm a scientist, talk to me' with Science Grrl. 2500 attendees of all ages, spoke to mainly children aged 4-12.

not known</gtr:impact><gtr:outcomeId>EkW4bdBX36L</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://sciencegrrl.co.uk/lancashire-science-festival/</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker - Antibiotic Discovery UK Ltd, London</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3E67E5D1-2908-4135-B57F-130BD60BE9EB</gtr:id><gtr:impact>Talk followed by Q&amp;amp;A session

n/a</gtr:impact><gtr:outcomeId>5462131c99fa86.63262369</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Manchester Science Festival</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B071030C-F31B-4D01-A30C-9129ECF70466</gtr:id><gtr:impact>October 2013 Manchester Science Festival at MOSI took part in 'I'm a scientist, talk to me' with Science Grrl. Over 100,000 attendees for the festival. Spoke to children and adults, mainly 5 -17 years old.

not known</gtr:impact><gtr:outcomeId>DtVGbyE88Rq</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>School Visit (Chester)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C35AA1CC-C256-43B5-8FD7-7B97FE7D0B23</gtr:id><gtr:impact>60 children attended - this was a presentation by me and interactive sessions with the children and teachers.

My visit was discussed by the headmaster at the whole school level and was reported to governors and in local news.</gtr:impact><gtr:outcomeId>AwgNJLDuJJd</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Press Release - New Centre for Drugs and Diagnostics</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8C676D10-D70F-4E03-A836-0E62DF7CF94B</gtr:id><gtr:impact>Press release of the new LSTM Centre for Drugs and Diagnostics

A breakfast launch meeting was hosted at the British Society for Parasitology in Nest Gardens, 2013 with 20+ representatives of Small-Medium Enterprises</gtr:impact><gtr:outcomeId>Y7gt9dboZAA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Paper Presentation</gtr:presentationType><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url> http://www.lstmliverpool.ac.uk/about-lstm/news-and-media/latest-news/launch-of-the-lstm-research-centre-for-drugs-and-diagnostics</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Barcelona Grifols ISR meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A44851E2-9D2A-497C-B20B-EC93FDD5C62B</gtr:id><gtr:impact>Aiming to engage commercial sponsorship in research with MRC help

DPFS 2014 application</gtr:impact><gtr:outcomeId>545cb2a9463470.51839092</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>CDC visit to LSTM and UoL</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>D4E0B8F4-754F-41AD-B98A-F2756EC54E4A</gtr:id><gtr:impact>Ed Ades from CDC visited the UK, spoke in Leicester, Univ of Liverpool and UoL.
P4 project grew as a result, now approaching DPFS application.

Further grants (e.g. Grifols sponsorship) and then DPFS application (rated fundable but not funded in 2013).</gtr:impact><gtr:outcomeId>545cb243ea1ca9.02485161</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Mental Floss Blog</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8A0D18A3-C93C-4D56-81C4-11EBACC7643F</gtr:id><gtr:impact>Link made between emphysema, worm infections and Vikings</gtr:impact><gtr:outcomeId>581c6d7f90b198.81655307</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:url>http://mentalfloss.com/article/77110/vikings-parasites-may-have-led-lung-problems-their-modern-descendants</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Speaker at the &quot;Closing the Global Health Divide through Partnership Driven Innovation Meeting&quot;</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3819099C-5390-4B64-B397-A2EA4BE09717</gtr:id><gtr:impact>The event represented a collective call for greater cross-border and cross-sector collaboration to ensure global preparedness for the inevitable resurgence of infectious diseases that disproportionally affect the poorest of the poor in developing countries. A series of presentations and interactive panels articulated the need for partnerships in global health and explored the challenges associated with R&amp;amp;D for infectious diseases.</gtr:impact><gtr:outcomeId>56b217b99adc11.71209681</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Speaker at the Joint International Tropical Medicine Meeting (JITMM), Thailand</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>B60A8A54-AC2D-478E-BD33-2DC67DD47EB8</gtr:id><gtr:impact>200+ attendees, mainly academics and pharma

n/a</gtr:impact><gtr:outcomeId>jzDyVYfgtCw</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>72000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust ISSF</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Liverpool School of Tropical Medicine</gtr:fundingOrg><gtr:id>E606E089-E667-4105-A8CB-05228859CA95</gtr:id><gtr:outcomeId>56a75a0f123687.38060835</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>70000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Grifols Investigator Lead Award</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Grifols</gtr:fundingOrg><gtr:id>4A9F06E1-E875-4442-BE87-8AD25B7F2EA8</gtr:id><gtr:outcomeId>58b82c75edb425.71000299</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>478278</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>EUR</gtr:currCode><gtr:currCountryCode>Austria</gtr:currCountryCode><gtr:currLang>de_AT</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>IMI EU FP7 &amp;quot;Model-based preclinical development of anti-tuberculosis drug combinations&amp;quot;</gtr:description><gtr:end>2017-04-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>7F551103-3224-4E3F-832E-BB37896177B6</gtr:id><gtr:outcomeId>CaYvCz3Fiuu</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>399449</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC newton Vietnam</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/N028376/1	</gtr:fundingRef><gtr:id>BC8C662B-4ACF-4389-97B7-4FA95936554A</gtr:id><gtr:outcomeId>58245129034831.16513195</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2016-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>382974</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>SBRI Vaccines for Global Epidemics - Preclinical Stage 1</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Innovate UK</gtr:fundingOrg><gtr:fundingRef>87113-544156</gtr:fundingRef><gtr:id>EA6EF83F-DBFA-477D-9630-7610833C10B7</gtr:id><gtr:outcomeId>58b81a6a157740.30916533</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2017-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCB Pharma Research Grant</gtr:description><gtr:end>2017-05-02</gtr:end><gtr:fundingOrg>UCB Pharma</gtr:fundingOrg><gtr:id>366F26FF-94B9-49B7-B433-7D1999A47BBE</gtr:id><gtr:outcomeId>581c67c129e6e3.28639317</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Patent license fee for HexaGard</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>UCB Pharma</gtr:fundingOrg><gtr:id>EA6A4611-8FEE-4313-B2F8-8066A479C3DB</gtr:id><gtr:outcomeId>58b8157ba64153.65466671</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2012-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>40000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Liverpool Health Partners Pump Priming Award</gtr:description><gtr:end>2015-02-02</gtr:end><gtr:fundingOrg>Liverpool Health Partners</gtr:fundingOrg><gtr:id>F5CC7DC4-8768-4F19-A190-D804C1F49DC9</gtr:id><gtr:outcomeId>58b82d573f0042.37618108</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2013-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Redx Pharma PLC</gtr:description><gtr:end>2022-07-02</gtr:end><gtr:fundingOrg>Redx Pharma Plc</gtr:fundingOrg><gtr:id>A0005E79-D412-4888-9903-0902EEC2DA2B</gtr:id><gtr:outcomeId>5825cbb78fd365.28263563</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>UCB Pharma Research Grant</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>UCB Pharma</gtr:fundingOrg><gtr:id>3AEFC9FD-E928-4763-9F2E-66E06DBA2CDE</gtr:id><gtr:outcomeId>56a75a755214c2.73727399</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2015-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>139400</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pathfinder</gtr:description><gtr:end>2017-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8B51A1C1-E14D-400B-B4C7-A66E100439A4</gtr:id><gtr:outcomeId>56a75b3bb20789.60116527</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>600000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust - Multi-User Equipment Grant</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>8BD36AB8-7D8A-4FC4-A7D7-014A2C6CD46B</gtr:id><gtr:outcomeId>545cf1568f8d92.05782488</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>602000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC DPFS</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>219B42AB-137D-42E0-AE8F-6E2A0343A58C</gtr:id><gtr:outcomeId>58b82cd44ce831.90886289</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>MRC Confidence in Concept Scheme</gtr:department><gtr:description>MRC CIC award</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MC-PC-12017</gtr:fundingRef><gtr:id>EE9ECA40-1557-43F7-887D-8825B1873FCC</gtr:id><gtr:outcomeId>545b5af2a90b15.73587291</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Provided are polymeric proteins that comprise two or more polypeptide monomer units, each monomer unit comprising two chimeric protein chains. Each chimeric polypeptide monomer unit comprises an Fc receptor binding portion comprising two immunoglobulin G heavy chain constant regions,wherein each immunoglobulin G heavy chain constant region comprises a cysteine residue which is linked via a disulfide bond to a cysteine residue of an immunoglobulin G heavy chain constant region of an adjacent polypeptide monomer unit. Each chimeric protein chain also comprises a modified immunoglobulin M tailpiece region, wherein the amino acid sequence of each chimeric polypeptide monomer comprises an alteration of the primary structure as compared to the native sequences from which the immunoglobulin G heavy chain constant region or immunoglobulin M tailpiece region are derived, and the alteration changes the number of glycosylation sites in a manner that promotes polymerisation. This promotion of polymerisation may lead to the generation of tetrameric, hexameric, and even dodecameric forms of the proteins. The proteins are suitable for medical uses,such as in the prevention or treatment of autoimmune diseases such as idiopathic thrombocytopenia. Also provided are methods of treatment using the polymeric proteins, and pharmaceutical compositions comprising the polymeric proteins.</gtr:description><gtr:grantRef>MC_PC_12017</gtr:grantRef><gtr:id>8005B54A-7084-46CD-9B4B-3828BD4A1E8F</gtr:id><gtr:impact>N/A</gtr:impact><gtr:licensed>Commercial In Confidence</gtr:licensed><gtr:outcomeId>58b8188ec5c464.67751649</gtr:outcomeId><gtr:patentId>WO2016009232 (A1)</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Polymeric proteins and uses thereof</gtr:title><gtr:yearProtectionGranted>2016</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>A drug name for hexameric Fc fusion</gtr:description><gtr:grantRef>MC_PC_12017</gtr:grantRef><gtr:id>1A618BD6-DCD6-4217-8E6A-F433C1A1F722</gtr:id><gtr:impact>This patent has been licensed to UCB Pharma for further development and they are talking it into national phase. We now collaborate with UCB Pharma</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>545b6135203c16.97226116</gtr:outcomeId><gtr:protection>Trade Mark</gtr:protection><gtr:title>HexaGard UK00003018151</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Polymeric Fc proteins</gtr:description><gtr:grantRef>MC_PC_12017</gtr:grantRef><gtr:id>F0F1A04A-741E-4039-8D07-6BC06510D127</gtr:id><gtr:impact>Non-exclusively licensed to UCB Pharma</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>545b5f8c2baaa4.87163904</gtr:outcomeId><gtr:patentId>WO2014060712</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>IMMUNOMODULATORY PROTEINS</gtr:title><gtr:yearProtectionGranted>2014</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External Scientific Advisory Board Member for the German Centre for Infection Research</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>E8A662F7-7A1F-45E0-95B9-61B7FBF9FABC</gtr:id><gtr:outcomeId>56b21dad3e2558.73697929</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the MMV External Scientific Advisory Board 2017 to date</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>DA41BD29-109C-446D-872B-A356D1F642E0</gtr:id><gtr:outcomeId>58c7ce99550d66.70277946</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Member of the MMV External Scientific Advisory Board (2008 to 2012)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>4DE54819-C6F4-483B-BF6F-F5A211CD7086</gtr:id><gtr:outcomeId>ffUTn4QM9DG</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>External advice to major funder with regard to antimalarial drug discovery projects</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>2B046392-74BF-46D0-A313-8872092C56A2</gtr:id><gtr:outcomeId>58221de4d4eb66.30605490</gtr:outcomeId><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Steering committee for an EU TB drug discovery consortium</gtr:description><gtr:geographicReach>Asia</gtr:geographicReach><gtr:id>65747CB8-1E99-4441-AC76-BCB408176819</gtr:id><gtr:outcomeId>Hfo78JfxWY5</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Macrofilaricide Drug Accelerator (MacDA)</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>AC17AB89-B2B4-4529-83C4-C853CC3545A8</gtr:id><gtr:outcomeId>56c5baf6710884.05438375</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>? UK management committee member for COST Action CM1307, 'Targeted chemotherapy towards diseases caused by endoparasites&amp;quot; - 2014- to date</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>79842EBD-C057-4FF2-A2FC-59F81FA7F5BF</gtr:id><gtr:outcomeId>56ddaeb04727c0.83647859</gtr:outcomeId><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://www.costcm1307.org/CM1307/Home.html</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>New drug target against malaria identified. There are several projects under way from hit identification to late leads. These projects are in collaboration with GSK and AZ and involve MMV (malaria PDP).</gtr:description><gtr:id>BAAD3E25-48F5-497E-9FF8-2E60DA028952</gtr:id><gtr:impact>New drug target against malaria identified. There are several projects under way from hit identification to late leads. These projects are in collaboration with GSK and AZ and involve MMV (malaria PDP).</gtr:impact><gtr:outcomeId>mA5nMPzVE5j</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>New drug against malaria</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://mmv.org</gtr:url><gtr:yearDevCompleted>2008</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Lead series identification. The series has activity against MDR TB and currently being assessed for in vivo efficacy</gtr:description><gtr:id>53871582-2304-47A1-AB36-42C8ED343ABF</gtr:id><gtr:impact>Lead series identification. The series has activity against MDR TB and currently being assessed for in vivo efficacy. The lead series have a novel mode of action.</gtr:impact><gtr:outcomeId>G8wUyhdZJQ6</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>New Drug against TB</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Data collection of organic compounds. The headspace (air above the sample or just air in the case of breath) is pulled through the instruments in a controlled fashion and the instrument response to that sample recorded.</gtr:description><gtr:id>0975F46E-A489-45C9-A888-2386AB1F5D74</gtr:id><gtr:impact>If successful in clinical trials will be able to convert tool to a handheld machine for diagnosis in rural settings</gtr:impact><gtr:outcomeId>VHmo6S3aDqU</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Enose</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>We have licensed patents related to this molecule with UCB Pharma. We are now collaborating with UCB to refine the molecule towards pre-clinical development</gtr:description><gtr:id>E72CF4DB-6D93-423C-903E-4AE6D35428CE</gtr:id><gtr:impact>A collaborative project with UCB Pharma</gtr:impact><gtr:outcomeId>545b62a7e87964.31494497</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>HexaGard</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:url>http://immunologynews.blogspot.co.uk/2013/11/generating-alternative-to-ivig-therapy.html</gtr:url><gtr:yearDevCompleted>2014</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>Background

The search for highly effective anti-malarial therapies has gathered pace and recent years have seen a number of promising single and combined therapies reach the late stages of development. A key drug development challenge is the need for early assessment of the clinical utility of new drug leads as it is often unclear for developers whether efforts should be focused on efficacy or metabolic stability/exposure or indeed whether the continuation of iterative QSAR (quantitative structure-activity and relationships) cycles of medicinal chemistry and biological testing will translate to improved clinical efficacy. Pharmacokinetic and pharmacodynamic (PK/PD)-based measurements available from in vitro studies can be used for such clinical predictions. However, these predictions often require bespoke mathematical PK/PD modelling expertise and are normally performed after candidate development and, therefore, not during the pre-clinical development phase when such decisions need to be made.

Methods

An internet-based tool has been developed using STELLA&amp;reg; software. The tool simulates multiple differential equations that describe anti-malarial PK/PD relationships where the user can easily input PK/PD parameters. The tool utilizes a simple stop-light system to indicate the efficacy of each combination of parameters. This tool, called OptiMal-PK, additionally allows for the investigation of the effect of drug combinations with known or custom compounds.

Results

The results of simulations obtained from OptiMal-PK were compared to a previously published and validated mathematical model on which this tool is based. The tool has also been used to simulate the PK/PD relationship for a number of existing anti-malarial drugs in single or combined treatment. Simulations were predictive of the published clinical parasitological clearance activities for these existing therapies.

Conclusions

OptiMal-PK is designed to be implemented by medicinal chemists and pharmacologists during the pre-clinical anti-malarial drug development phase to explore the impact of different PK/PD parameters upon the predicted clinical activity of any new compound. It can help investigators to identify which pharmacological features of a compound are most important to the clinical performance of a new chemical entity and how partner drugs could potentially improve the activity of existing therapies.</gtr:description><gtr:id>6FB698F2-E2A2-49F9-808F-01FC7B000867</gtr:id><gtr:impact>The software has been used by a number of users for both teaching and research purposes. The use of the model has lowered the number of animal experiments in my laboratory but it is difficult to estimate how many in vivo experiments it has reduced externally. We are currently working to promote the on-line tool.</gtr:impact><gtr:outcomeId>58c6983c6c13b7.44669497</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens</gtr:title><gtr:type>Computer model/algorithm</gtr:type><gtr:url>http://optimalpk.lstmed.ac.uk</gtr:url><gtr:yearFirstProvided>2016</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Multi-User Equipment Grant entitled 'Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens'

We have set up to our knowledge the first dedicated HG3 imaging facility, able to sort and image HG3 pathogens, e.g. TB and HIV</gtr:description><gtr:id>6DE8DF4C-5EC1-4753-ABD0-AAC7313280A7</gtr:id><gtr:impact>It has just been set up, impact will be described next year</gtr:impact><gtr:outcomeId>545cf60f2a3ba6.86792804</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Multi-User Equipment Grant entitled 'Supporting excellence in basic and clinical research: A flow cytometry/sorting and cell imaging platform for the genotypic and phenotypic analysis of Hazard Group 3 pathogens'</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have generated a stable GFP-transformed Mtb. This allows the real-time monitoring of Mtb using fluorescence-based technologies.</gtr:description><gtr:id>DCA563A2-AB28-442D-A1AD-0E008AC54A05</gtr:id><gtr:impact>The GFP-tagged Mtb allows the investigator to &amp;quot;follow&amp;quot; the Mtb infection, replication and viability in a variety of model systems, e.g. intracellular systems, whole blood assay etc.</gtr:impact><gtr:outcomeId>rDFSq18RGLT</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>GFP-Mycobacterium tuberculosis</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Collects organic volatile compounds - the headspace (air above the sample or just air in the case of breath) is pulled through the instruments in a controlled fashion and the instrument response to that sample recorded.</gtr:description><gtr:id>5AA1658A-269E-4C9F-8290-5D95F674FA93</gtr:id><gtr:impact>Ability to run samples in UHCW in cat III lab to profile organic compounds produced by disease</gtr:impact><gtr:outcomeId>b4kBNf51f8Z</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>enose technology</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We have set up a high-content imaging platform for the measurement of intracellular M. tuberculosis. A clinically significant sub-population of Mtb is found inside host cells, e.g. macrophages. Using our HC platform we are now able to identify drugs that are active against this sub-population. 

This platform will have significant utility in identifying drugs that can treat drug persistent Mtb.</gtr:description><gtr:id>91D6A3AF-2B88-4F6A-A8E4-C94CAF5B263E</gtr:id><gtr:impact>This system is currently being evaluated as an improved in vitro system for the clinical prediction of drug activity. If found to be predictive, this system is likely to be incorporated into drug discovery pipelines used by industry and academia.</gtr:impact><gtr:outcomeId>aYfDGjonJtr</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>High-content imaging platform for intracellular M. tuberculosis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B8939178-E303-43D0-B880-9139427956E3</gtr:id><gtr:title>Rational Design, Synthesis, and Biological Evaluation of Heterocyclic Quinolones Targeting the Respiratory Chain of Mycobacterium tuberculosis.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/76666ef804145a8e573cb6d669ebbac4"><gtr:id>76666ef804145a8e573cb6d669ebbac4</gtr:id><gtr:otherNames>Hong WD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>5a9eada589cfa5.57609599</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3438A7E6-263C-49BC-B9E1-200079CA0123</gtr:id><gtr:title>Immunoactivating peptide p4 augments alveolar macrophage phagocytosis in two diverse human populations.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ea018924346ae16434d1dea747ab4a7"><gtr:id>5ea018924346ae16434d1dea747ab4a7</gtr:id><gtr:otherNames>Bangert M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_23584_24_23817378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53D1DB97-43C5-4861-B2D5-6E7A7D296DCA</gtr:id><gtr:title>Targeting the mitochondrial electron transport chain of Plasmodium falciparum: new strategies towards the development of improved antimalarials for the elimination era.</gtr:title><gtr:parentPublicationTitle>Future medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f0f08f38aed1db3df1b22aebf96ff04"><gtr:id>0f0f08f38aed1db3df1b22aebf96ff04</gtr:id><gtr:otherNames>Nixon GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1756-8919</gtr:issn><gtr:outcomeId>545cedc5b59060.19739546</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5F8F024-81FD-4499-9DC9-051A77D71B46</gtr:id><gtr:title>Augmented Passive Immunotherapy with P4 Peptide Improves Phagocyte Activity in Severe Sepsis.</gtr:title><gtr:parentPublicationTitle>Shock (Augusta, Ga.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac09ecea7dd8ebb8d409ed0b84ca496d"><gtr:id>ac09ecea7dd8ebb8d409ed0b84ca496d</gtr:id><gtr:otherNames>Morton B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1073-2322</gtr:issn><gtr:outcomeId>57ce72388f2e84.47990589</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAB059BB-903A-4341-8F66-6131E2A1D186</gtr:id><gtr:title>A yeast expression system for functional and pharmacological studies of the malaria parasite Ca&amp;sup2;?/H? antiporter.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d436bdab223cade1091ca9ed24b61485"><gtr:id>d436bdab223cade1091ca9ed24b61485</gtr:id><gtr:otherNames>Salcedo-Sora JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>545cedc5453002.56997863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C50CE67-FCB9-4A5D-B669-AF156956BCF6</gtr:id><gtr:title>ESICM LIVES 2016: part one</gtr:title><gtr:parentPublicationTitle>Intensive Care Medicine Experimental</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5caecf36047e3dec91b893b42b9da358"><gtr:id>5caecf36047e3dec91b893b42b9da358</gtr:id><gtr:otherNames>Bos L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58b82b332df164.53528376</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC558ABF-CE5A-4AE7-9048-298AAFB6CA6A</gtr:id><gtr:title>Engineering the fragment crystallizable (Fc) region of human IgG1 multimers and monomers to fine-tune interactions with sialic acid-dependent receptors.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cace5d896d7205ecd41ab2f507a4c8f5"><gtr:id>cace5d896d7205ecd41ab2f507a4c8f5</gtr:id><gtr:otherNames>Blundell PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>59ba5177012a77.68825034</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C198409C-47B2-4013-8B2E-545DB54FF9F1</gtr:id><gtr:title>Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a7d8df257e748e69522231f52f1a1bc7"><gtr:id>a7d8df257e748e69522231f52f1a1bc7</gtr:id><gtr:otherNames>Sloan DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>5a9eac7aa15476.01316275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C7451AAA-849E-4B05-8E02-59986562A485</gtr:id><gtr:title>Immunoglobulin M: Restrainer of Inflammation and Mediator of Immune Evasion by Plasmodium falciparum Malaria.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41ad23200a029cf46f495b74e21df3c2"><gtr:id>41ad23200a029cf46f495b74e21df3c2</gtr:id><gtr:otherNames>Pleass RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>56a758d17f1ad0.18534415</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D6A458F-83D1-4926-82AF-880B5ACDA2D8</gtr:id><gtr:title>Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba120ad0efef8b4c8420f4874b56f752"><gtr:id>ba120ad0efef8b4c8420f4874b56f752</gtr:id><gtr:otherNames>Llewellyn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56a758d1a65f79.68666771</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>816069BE-2D75-45BB-B896-012F6D755748</gtr:id><gtr:title>Glutathione transport: a new role for PfCRT in chloroquine resistance.</gtr:title><gtr:parentPublicationTitle>Antioxidants &amp; redox signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23dfa25c0defe9c651c5f776319d0e7c"><gtr:id>23dfa25c0defe9c651c5f776319d0e7c</gtr:id><gtr:otherNames>Patzewitz EM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1523-0864</gtr:issn><gtr:outcomeId>545cedc56b6264.21038094</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37C6E466-0BB2-45D6-8C70-81AE2D13EE80</gtr:id><gtr:title>P4-mediated antibody therapy in an acute model of invasive pneumococcal disease.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5ea018924346ae16434d1dea747ab4a7"><gtr:id>5ea018924346ae16434d1dea747ab4a7</gtr:id><gtr:otherNames>Bangert M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>pm_23584_24_22457294</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C13A250-115E-4914-A1EB-6E1291EF4B33</gtr:id><gtr:title>OptiMal-PK: an internet-based, user-friendly interface for the mathematical-based design of optimized anti-malarial treatment regimens.</gtr:title><gtr:parentPublicationTitle>Malaria journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e3511efcc710829c2226c3891942d74"><gtr:id>1e3511efcc710829c2226c3891942d74</gtr:id><gtr:otherNames>Aljayyoussi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1475-2875</gtr:issn><gtr:outcomeId>582445d93f6472.83443694</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D7DA3F5B-38C2-4779-9BAF-C19937AE0AD4</gtr:id><gtr:title>Binding of Plasmodium falciparum Merozoite Surface Proteins DBLMSP and DBLMSP2 to Human Immunoglobulin M Is Conserved among Broadly Diverged Sequence Variants.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e44dc5801845f58f7d9500ac50bb6478"><gtr:id>e44dc5801845f58f7d9500ac50bb6478</gtr:id><gtr:otherNames>Crosnier C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>581c6487513618.66245506</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B77B801F-0FF4-4D99-9EA0-83C42A96F075</gtr:id><gtr:title>The antimalarial drug quinine interferes with serotonin biosynthesis and action.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4209d840086f6e35553e2692b597fb8"><gtr:id>a4209d840086f6e35553e2692b597fb8</gtr:id><gtr:otherNames>Islahudin F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>545764a45327c2.50966653</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D40B003-FE8A-4D9C-A85E-CCB73038BF0A</gtr:id><gtr:title>Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5e218f46ddd0cc184cc414306d19603"><gtr:id>d5e218f46ddd0cc184cc414306d19603</gtr:id><gtr:otherNames>Antoine T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>545cedc4715fd1.43304322</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D81B81EB-52E2-4669-854F-B3E35D3D7AE4</gtr:id><gtr:title>A Quinoline Carboxamide Antimalarial Drug Candidate Uniquely Targets Plasmodia at Three Stages of the Parasite Life Cycle.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06c05b3620f7d7cdab1f4b38cdaeaef"><gtr:id>a06c05b3620f7d7cdab1f4b38cdaeaef</gtr:id><gtr:otherNames>O'Neill PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>56b1f123e36193.28350084</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C3F25D1-3A93-4B1B-801C-FF3EA7ABCD96</gtr:id><gtr:title>The proliferating cell hypothesis: a metabolic framework for Plasmodium growth and development.</gtr:title><gtr:parentPublicationTitle>Trends in parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d436bdab223cade1091ca9ed24b61485"><gtr:id>d436bdab223cade1091ca9ed24b61485</gtr:id><gtr:otherNames>Salcedo-Sora JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-4922</gtr:issn><gtr:outcomeId>545ce4797b6773.55638280</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E1B9700-79AD-41D6-83D7-50585F713916</gtr:id><gtr:title>Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be463e4a2b8585bf6dcdae1c2ce8816a"><gtr:id>be463e4a2b8585bf6dcdae1c2ce8816a</gtr:id><gtr:otherNames>Czajkowsky DM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>56a758d1ce8a88.46778258</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>684DF179-121E-42B6-8907-20B030355002</gtr:id><gtr:title>Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials.</gtr:title><gtr:parentPublicationTitle>Molecular medicine (Cambridge, Mass.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6df89b6324556c806bdd3836640b9da3"><gtr:id>6df89b6324556c806bdd3836640b9da3</gtr:id><gtr:otherNames>Copple IM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1076-1551</gtr:issn><gtr:outcomeId>545cedc591e150.49167519</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0D39AD77-44EA-43A7-9F22-A6445893ECEA</gtr:id><gtr:title>A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a06c05b3620f7d7cdab1f4b38cdaeaef"><gtr:id>a06c05b3620f7d7cdab1f4b38cdaeaef</gtr:id><gtr:otherNames>O'Neill PM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a9ead1b184c34.70901898</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CF32BC2E-A6C6-4643-AF07-45AC03749B77</gtr:id><gtr:title>Corrigendum: A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>58c7cda72f7a50.40072733</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>562C6E22-B748-43ED-AFC0-141CD81ED9D5</gtr:id><gtr:title>Artemisinin activity-based probes identify multiple molecular targets within the asexual stage of the malaria parasites Plasmodium falciparum 3D7.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>582219d0dc3c80.24009746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05459E38-0044-4178-A16A-8D83AE1C99C8</gtr:id><gtr:title>Carbamoyl Triazoles, Known Serine Protease Inhibitors, Are a Potent New Class of Antimalarials.</gtr:title><gtr:parentPublicationTitle>Journal of medicinal chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5211771b9988c81aea61d371b9ad55e4"><gtr:id>5211771b9988c81aea61d371b9ad55e4</gtr:id><gtr:otherNames>McConville M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-2623</gtr:issn><gtr:outcomeId>56b1f1003b46c4.21082368</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9559196D-953F-4C16-AE13-CC6B72DDF6EB</gtr:id><gtr:title>Antimalarial pharmacology and therapeutics of atovaquone.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0f0f08f38aed1db3df1b22aebf96ff04"><gtr:id>0f0f08f38aed1db3df1b22aebf96ff04</gtr:id><gtr:otherNames>Nixon GL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>545cedc4bdfb35.44074649</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D831777-4847-48C1-BD4C-25E9F4A95243</gtr:id><gtr:title>An analysis of the binding characteristics of a panel of recently selected ICAM-1 binding Plasmodium falciparum patient isolates.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e20b30d092a3bd63e226dfd6981a5e3b"><gtr:id>e20b30d092a3bd63e226dfd6981a5e3b</gtr:id><gtr:otherNames>Madkhali AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56a758d23a8918.69728520</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>06904372-574D-4B98-A376-6FD0BF33CD5F</gtr:id><gtr:title>Immunomodulatory adjuvant therapy in severe community-acquired pneumonia.</gtr:title><gtr:parentPublicationTitle>Expert review of respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac09ecea7dd8ebb8d409ed0b84ca496d"><gtr:id>ac09ecea7dd8ebb8d409ed0b84ca496d</gtr:id><gtr:otherNames>Morton B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1747-6348</gtr:issn><gtr:outcomeId>545224e387c403.50714181</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>00429818-20CD-45F0-A0BD-54BAAB4DB206</gtr:id><gtr:title>PFMDR1 POLYMORPHISMS INFLUENCE ON IN VITRO SENSITIVITY OF THAI PLASMODIUM FALCIPARUM ISOLATES TO PRIMAQUINE, SITAMAQUINE AND TAFENOQUINE.</gtr:title><gtr:parentPublicationTitle>The Southeast Asian journal of tropical medicine and public health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6059000f7b5ed7c42535268802fac5a8"><gtr:id>6059000f7b5ed7c42535268802fac5a8</gtr:id><gtr:otherNames>Kaewpruk N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0125-1562</gtr:issn><gtr:outcomeId>582219d13bdb22.09954819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>81528CB7-994B-4609-8096-2126C6054194</gtr:id><gtr:title>A Click Chemistry-Based Proteomic Approach Reveals that 1,2,4-Trioxolane and Artemisinin Antimalarials Share a Common Protein Alkylation Profile.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (Weinheim an der Bergstrasse, Germany)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4212d48fb2be0f6cd4cdc97f750f256b"><gtr:id>4212d48fb2be0f6cd4cdc97f750f256b</gtr:id><gtr:otherNames>Ismail HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0044-8249</gtr:issn><gtr:outcomeId>582445d92037f5.81178827</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A91419F-5A05-4956-80CE-38E81B2B9DB6</gtr:id><gtr:title>Correction: An Analysis of the Binding Characteristics of a Panel of Recently Selected ICAM-1 Binding Plasmodium falciparum Patient Isolates.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e20b30d092a3bd63e226dfd6981a5e3b"><gtr:id>e20b30d092a3bd63e226dfd6981a5e3b</gtr:id><gtr:otherNames>Madkhali AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>581c6382759d42.63711129</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B98A3426-68C6-421E-AFCA-C52D5C075707</gtr:id><gtr:title>The folate metabolic network of Falciparum malaria.</gtr:title><gtr:parentPublicationTitle>Molecular and biochemical parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d436bdab223cade1091ca9ed24b61485"><gtr:id>d436bdab223cade1091ca9ed24b61485</gtr:id><gtr:otherNames>Salcedo-Sora JE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0166-6851</gtr:issn><gtr:outcomeId>545cedc51c7b27.78735303</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B793497F-A24B-4FD6-8712-32146E64F4A0</gtr:id><gtr:title>Glycan-independent binding and internalization of human IgM to FCMR, its cognate cellular receptor.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/af3543a28406477a31dad591140f6a66"><gtr:id>af3543a28406477a31dad591140f6a66</gtr:id><gtr:otherNames>Lloyd KA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>58b819982ed574.90607652</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B3046E7-6779-4616-B406-6D3FF272912E</gtr:id><gtr:title>Influence of theGene on In Vitro Sensitivities of Piperaquine in Thai Isolates of.</gtr:title><gtr:parentPublicationTitle>The American journal of tropical medicine and hygiene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/690909a391a0c1aab3ba74b8b327a637"><gtr:id>690909a391a0c1aab3ba74b8b327a637</gtr:id><gtr:otherNames>Mungthin M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0002-9637</gtr:issn><gtr:outcomeId>58c7cda78786e3.48202906</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6EE08342-DCFC-44F6-ACE4-781638525F59</gtr:id><gtr:title>Novel inhibitors of the Plasmodium falciparum electron transport chain.</gtr:title><gtr:parentPublicationTitle>Parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/001da32001d5fbced797c03667da79c5"><gtr:id>001da32001d5fbced797c03667da79c5</gtr:id><gtr:otherNames>Stocks PA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-1820</gtr:issn><gtr:outcomeId>545ce4dea57cb8.50448986</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC9732B3-850E-4CD5-9372-2DCB41A28FD6</gtr:id><gtr:title>Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.</gtr:title><gtr:parentPublicationTitle>Journal of controlled release : official journal of the Controlled Release Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/eed932aa1910feed9372b3da176beb48"><gtr:id>eed932aa1910feed9372b3da176beb48</gtr:id><gtr:otherNames>Foss S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-3659</gtr:issn><gtr:outcomeId>56a758d1587146.39036715</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>490FCA84-35D0-4E66-B47D-72573F0AD9DF</gtr:id><gtr:title>A simple breath test for tuberculosis using ion mobility: A pilot study.</gtr:title><gtr:parentPublicationTitle>Tuberculosis (Edinburgh, Scotland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/88ce30a76d276e0ea052acc81bb19e3f"><gtr:id>88ce30a76d276e0ea052acc81bb19e3f</gtr:id><gtr:otherNames>Sahota AS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1472-9792</gtr:issn><gtr:outcomeId>5825b5c9c3fa64.04692337</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B01E19A0-57FC-41BE-8DE4-CC758F5530B1</gtr:id><gtr:title>Antitubercular pharmacodynamics of phenothiazines.</gtr:title><gtr:parentPublicationTitle>The Journal of antimicrobial chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e4fbe34e90e642a091101b0d5ce20fd0"><gtr:id>e4fbe34e90e642a091101b0d5ce20fd0</gtr:id><gtr:otherNames>Warman AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0305-7453</gtr:issn><gtr:outcomeId>545cedc4e902e0.30614390</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E549596-4DFD-4C60-B1A1-78EA4F88408D</gtr:id><gtr:title>Suboptimal Exposure to Anti-TB Drugs in a TBM/HIV+ Population Is Not Related to Antiretroviral Therapy.</gtr:title><gtr:parentPublicationTitle>Clinical pharmacology and therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/01e4ebb681ccf6798567dcd0ff136045"><gtr:id>01e4ebb681ccf6798567dcd0ff136045</gtr:id><gtr:otherNames>T?r?k ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0009-9236</gtr:issn><gtr:outcomeId>58c7cda7b071f0.39970043</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EF49C1C4-E8B1-4C56-BDD0-83F7DA5BD58F</gtr:id><gtr:title>2-Pyridylquinolone
 antimalarials with improved antimalarial activity and physicochemical properties</gtr:title><gtr:parentPublicationTitle>MedChemComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8b7d9a6884c2f596793e573ed8cbe50"><gtr:id>d8b7d9a6884c2f596793e573ed8cbe50</gtr:id><gtr:otherNames>Charoensutthivarakul S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2040-2503</gtr:issn><gtr:outcomeId>56b1f1a3c08cb4.35220632</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_12017</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C4255A20-7C03-4147-BA26-8D72C9457F1C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Health Uncodeable</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>06E85C67-BEDD-4C93-990D-B74FCF876924</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>HRCS Research Uncodeable</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>